Please see full Important Safety Information on page 7, and click here for full Prescribing Information.

For more information, visit TRUMENBA.com

Is your child at risk for potentially deadly MenB?1

MenB disease is spread by typical adolescent behavior like sharing food or drinks, and living in close quarters.2

Talk to your healthcare provider about vaccinating your child against meningococcal group B (MenB) disease

INDICATION• Trumenba is a vaccine indicated for individuals 10 through 25 years of age for

active immunization to prevent invasive disease caused by Neisseria meningitidis group B

• Trumenba is approved based upon demonstrated immune response against four group B strains representative of prevalent strains in the US. The effectiveness of Trumenba against diverse group B strains has not been confirmed

IMPORTANT SAFETY INFORMATION• Trumenba should not be given to anyone with a history of a severe allergic

reaction after a previous dose of Trumenba

• Individuals with weakened immune systems may have a reduced immune response

What is MenB disease?• MenB disease is a bacterial infection that attacks the brain and spinal cord.

It can also cause an infection of the blood5

• Typical adolescent and young adult behavior, like kissing, sharing drinks or utensils, and communal living, can spread the bacteria that cause MenB disease2

• Early symptoms may seem like the flu, but can lead to hospitalization or death within 24 hours5,6

• MenB disease may lead to7:

• On average, 1 in 10 adolescents and young adults who develop MenB disease will die from it8

• MenB disease represents 40% of all meningococcal disease cases among adolescents and young adults in the United States9

3

Are you sure your child is protected against uncommon, but deadly, MenB?Until 2014, there was no vaccine approved for MenB disease in the United States. And even if your child received a meningococcal vaccine (MCV4), he or she may be unprotected against MenB disease. TRUMENBA can help protect your child against this potentially deadly disease.3,4

Loss of limbs Brain damage Scarring Hearing loss

INDICATION• Trumenba is a vaccine indicated for individuals 10 through 25 years of

age for active immunization to prevent invasive disease caused by Neisseria meningitidis group B

• Trumenba is approved based upon demonstrated immune response against four group B strains representative of prevalent strains in the US. The effectiveness of Trumenba against diverse group B strains has not been confirmed

IMPORTANT SAFETY INFORMATION • Individuals with weakened immune systems may have a reduced

immune response

• The most common adverse reactions were pain at the injection site, fatigue, headache, muscle pain, and chills

2

Please see full Important Safety Information on page 7, and click here for full Prescribing Information.

What is TRUMENBA?TRUMENBA is a US Food and Drug Administration (FDA)-approved vaccine for the prevention of MenB disease, which was clinically studied in the United States and Europe. Patients who participated in TRUMENBA clinical trials were adolescents and young adults.4

Safety profile• Safety data demonstrated that TRUMENBA was generally well tolerated4

• The most commonly reported side effects were pain at the injection site, fatigue, headache, muscle pain, and chills4

• The safety of TRUMENBA was assessed in 7 clinical trials that included over 4000 adolescents and young adults4

• TRUMENBA is the only MenB vaccine studied with other adolescent vaccines—meningococcal ACWY vaccine (MCV4), HPV vaccine (4vHPV), and tetanus, diphtheria, and pertussis vaccine (Tdap)1,4

TRUMENBA follows a two or three dose scheduleTRUMENBA is available in a 2-dose or 3-dose schedule (0.5 mL each). Discuss with your child’s healthcare provider which schedule may be appropriate for your child. It is important to complete the vaccine series.4

2-dose schedule

3-dose schedule

DOSE DOSE

at day 1

21

DOSE

at day 1

1

6 months after dose 1

DOSE

21-2 months after dose 1

DOSE

36 months after dose 1

4 5

Please see full Important Safety Information on page 7, and click here for full Prescribing Information.Please see full Important Safety Information on page 7, and click here for full Prescribing Information.

FDA-approved to help protect adolescents and young adults4

The Centers for Disease Control and Prevention (CDC) recommends that a MenB vaccine may be administered to adolescents and young adults.1

INDICATION• Trumenba is a vaccine indicated for individuals 10 through 25 years

of age for active immunization to prevent invasive disease caused by Neisseria meningitidis group B

• Trumenba is approved based upon demonstrated immune response against four group B strains representative of prevalent strains in the US. The effectiveness of Trumenba against diverse group B strains has not been confirmed

IMPORTANT SAFETY INFORMATION • Data are not available on the safety and effectiveness of using Trumenba

and other meningococcal group B vaccines interchangeably to complete the vaccination series

6

Please see full Important Safety Information on page 7, and click here for full Prescribing Information.

7

Please see full Important Safety Information on page 7, and click here for full Prescribing Information.

TRUMENBA® vaccination for adolescents and young adultsSharing things like drinks and utensils, and kissing, can spread the bacteria that cause MenB disease. Activities that involve close contact, like communal living, participation on sports teams or in music groups, also can put adolescents and young adults at increased risk.2

Find out where to get TRUMENBA®

Call 1-800-683-8572 Mon-Fri 8 AM-9 PM ET

Ask your child’s healthcare provider about vaccinating with TRUMENBA

INDICATION

• Trumenba is a vaccine indicated for individuals 10 through 25 years of age for active immunization to prevent invasive disease caused by Neisseria meningitidis group B

• Trumenba is approved based upon demonstrated immune response against four group B strains representative of prevalent strains in the US. The effectiveness of Trumenba against diverse group B strains has not been confirmed

IMPORTANT SAFETY INFORMATION

• Trumenba should not be given to anyone with a history of a severe allergic reaction after a previous dose of Trumenba

• Individuals with weakened immune systems may have a reduced immune response

• The most common adverse reactions were pain at the injection site, fatigue, headache, muscle pain, and chills

• Data are not available on the safety and effectiveness of using Trumenba and other meningococcal group B vaccines interchangeably to complete the vaccination series

• Tell your healthcare provider if you are pregnant, or plan to become pregnant

• Ask your healthcare provider about the risks and benefits of Trumenba. Only a healthcare provider can decide if Trumenba is right for you or your child

PP-TRU-USA-0746-01 © 2016 Pfizer Inc. All rights reserved. June 2016

Symptoms of MenB may seem like the flu, but can lead to death within 24 hours.5,6

You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit www.vaers.hhs.gov or call 1-800-822-7967.

Call 1-844-TRUMENBA (878-6362), 9 am to 7 pm ET, Monday through Friday, for more information.

Please see full Important Safety Information on page 7, and click here for full Prescribing Information.

References: 1. MacNeil JR, Rubin L, Folaranmi T, et al. Centers for Disease Control and Prevention. Use of serogroup B meningococcal vaccines in adolescents and young adults: recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2015;64(41):1171-1177. 2. Soeters HM, McNamara LA, Whaley M, et al. Serogroup B meningococcal disease outbreak and carriage evaluation at a college—Rhode Island, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(22):606-607. 3. Folaranmi T, Rubin L, Martin SW, et al. Use of serogroup B meningococcal vaccines in persons aged ≥10 years at increased risk for serogroup B meningococcal disease: recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(22):608-612. 4. Trumenba [prescribing information]. Philadelphia, PA: Pfizer Inc; 2016. 5. Centers for Disease Control and Prevention. Meningococcal disease. Centers for Disease Control and Prevention website. http://www.cdc.gov/meningococcal/index.html. Updated March 4, 2016. Accessed March 28, 2016. 6. Thompson MJ, Ninis N, Perera R, et al. Clinical recognition of meningococcal disease in children and adolescents. Lancet. 2006;367(9508):397-403. 7. Bettinger JA, Scheifele DW, Le Saux N, et al. The disease burden of invasive meningococcal serogroup B disease in Canada. Pediatr Infect Dis J. 2013;32(1):e20-e25. 8. Cohn AC, MacNeil JR, Harrison LH, et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis. 2010;50(2):184-191. 9. Centers for Disease Control and Prevention. Epidemiology of serogroup B meningococcal disease, United States. Advisory Committee on Immunization Practices, October 30, 2014. Centers for Disease Control and Prevention website. http://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2014-10/mening-02-MacNeil.pdf. Accessed May 3, 2016.

INDICATION• Trumenba is a vaccine indicated for individuals 10 through 25 years of age for active

immunization to prevent invasive disease caused by Neisseria meningitidis group B

• Trumenba is approved based upon demonstrated immune response against four group B strains representative of prevalent strains in the US. The effectiveness of Trumenba against diverse group B strains has not been confirmed

IMPORTANT SAFETY INFORMATION• Trumenba should not be given to anyone with a history of a severe allergic reaction

after a previous dose of Trumenba

• Individuals with weakened immune systems may have a reduced immune response

Are you sure your child is protected? Talk to a healthcare provider about vaccinating

your child with TRUMENBA

For more information, visitTRUMENBA.com